Glaukos Corporation

Equities

GKOS

US3773221029

Medical Equipment, Supplies & Distribution

Market Closed - Nyse Other stock markets 04:00:02 2024-04-26 pm EDT			5-day change	1st Jan Change
99.48 ^USD	-0.63%		+3.09%	+25.15%

Apr. 11	Mizuho Securities Adjusts Price Target on Glaukos to $100 From $85, Maintains Neutral Rating	MT
Apr. 11	Glaukos Insider Sold Shares Worth $6,008,359, According to a Recent SEC Filing	MT

Glaukos Corporation Reports Earnings Results for the Fourth Quarter and Full Year Ended December 31, 2023

February 21, 2024 at 04:05 pm EST

Glaukos Corporation reported earnings results for the fourth quarter and full year ended December 31, 2023. For the fourth quarter, the company reported sales was USD 82.37 million compared to USD 71.23 million a year ago. Net loss was USD 36.78 million compared to USD 31.46 million a year ago. Basic loss per share from continuing operations was USD 0.75 compared to USD 0.66 a year ago. Diluted loss per share from continuing operations was USD 0.75 compared to USD 0.66 a year ago.
For the full year, sales was USD 314.71 million compared to USD 282.86 million a year ago. Net loss was USD 134.66 million compared to USD 99.2 million a year ago. Basic loss per share from continuing operations was USD 2.78 compared to USD 2.09 a year ago. Diluted loss per share from continuing operations was USD 2.78 compared to USD 2.09 a year ago.

Latest news about Glaukos Corporation

Mizuho Securities Adjusts Price Target on Glaukos to $100 From $85, Maintains Neutral Rating	Apr. 11	MT
Glaukos Insider Sold Shares Worth $6,008,359, According to a Recent SEC Filing	Apr. 11	MT
Sector Update: Health Care Stocks Rise Wednesday Afternoon	Apr. 03	MT
Glaukos Says iDose TR Assigned Permanent J-Code From US Centers for Medicare and Medicaid Services	Apr. 03	MT
Glaukos Corporation Receives Permanent J-Code for iDose TR (travoprost intracameral implant)	Apr. 03	CI
Glaukos Insider Sold Shares Worth $1,153,557, According to a Recent SEC Filing	Mar. 08	MT
Glaukos Insider Sold Shares Worth $736,000, According to a Recent SEC Filing	Feb. 29	MT
Glaukos Insider Sold Shares Worth $423,487, According to a Recent SEC Filing	Feb. 27	MT
Wells Fargo Hikes Price Target on Glaukos to $103 From $83, Maintains Overweight Rating	Feb. 22	MT
Needham Raises Price Target on Glaukos to $108 From $105, Maintains Buy Rating	Feb. 22	MT
Glaukos Q4 Non-GAAP Loss Widens, Sales Increase	Feb. 21	MT
Earnings Flash (GKOS) GLAUKOS CORPORATION Reports Q4 Revenue $82.4M, vs. Street Est of $78.5M	Feb. 21	MT
Transcript : Glaukos Corporation, Q4 2023 Earnings Call, Feb 21, 2024	Feb. 21
Glaukos Corporation Reaffirms Financial Guidance for 2024	Feb. 21	CI
Glaukos Corporation Reports Earnings Results for the Fourth Quarter and Full Year Ended December 31, 2023	Feb. 21	CI
Glaukos Insider Sold Shares Worth $436,041, According to a Recent SEC Filing	Jan. 18	MT
Transcript : Glaukos Corporation Presents at J.P. Morgan 42nd Annual Healthcare Conference 2024, Jan-09-2024 05:15 PM	Jan. 09
Glaukos Preliminary Q4 Net Sales Top Estimates; 2024 Revenue Outlook Reaffirmed; Shares Rise	Jan. 09	MT
Glaukos Corporation Announces Preliminary and Unaudited Net Sales for the Fourth Quarter and Full Year of 2023; Reaffirms Net Sales Guidance for the Year 2024	Jan. 09	CI
Glaukos Insider Sold Shares Worth $7,334,253, According to a Recent SEC Filing	Jan. 04	MT
North American Morning Briefing : Dow Futures Fall -2-	Dec. 22	DJ
Piper Sandler Raises Price Target on Glaukos to $105 From $90, Maintains Overweight Rating	Dec. 22	MT
JPMorgan Upgrades Glaukos to Overweight From Neutral, Raises Price Target to $91 From $66	Dec. 21	MT
Sector Update: Health Care Stocks Slipping Late Afternoon	Dec. 14	MT
Sector Update: Health Care	Dec. 14	MT

Chart Glaukos Corporation

Duration

Period

More charts

Company Profile

Glaukos Corporation is an ophthalmic pharmaceutical and medical technology company. It develops novel, dropless therapies and commercializing associated products for the treatment of glaucoma, corneal disorders and retinal disease. Its product candidates include Micro-Invasive Glaucoma Surgery products that involve the insertion of a micro-scale device designed to reduce intraocular pressure (IOP) by restoring the natural aqueous humor outflow pathways for patients suffering from glaucoma and procedural pharmaceuticals based on an intracameral drug delivery technology designed to reduce IOP by delivering therapeutic levels of glaucoma medication from inside the eye over an extended period of time. Its products include transdermal pharmaceuticals that are applied to the eyelid and designed to treat glaucoma, dry eye, presbyopia and other ocular surface diseases and disorders and micro-invasive, bio-erodible sustained release drug delivery implants to improve the vision of patients.

Sector

Medical Equipment, Supplies & Distribution

Calendar

2024-05-01 - Q1 2024 Earnings Release

Related indices

Russell 2000

More about the company

Income Statement Evolution

More financial data

Ratings for Glaukos Corporation

Trading Rating

Investor Rating

ESG Refinitiv

B+

More Ratings

Analysts' Consensus

Sell

Buy

Mean consensus

OUTPERFORM

Number of Analysts

Last Close Price

99.48 USD

Average target price

106.6 USD

Spread / Average Target

+7.20%

Consensus

EPS Revisions

Estimates Revisions

Quarterly earnings - Rate of surprise

Company calendar

Sector Medical Devices & Implants

	1st Jan change	Capi.
GLAUKOS CORPORATION	+25.15%	4.99B
STRYKER CORPORATION	+12.07%	128B
SMITH & NEPHEW PLC	-9.04%	10.65B
IMEIK TECHNOLOGY DEVELOPMENT CO.,LTD.	+0.91%	8.82B
INSPIRE MEDICAL SYSTEMS, INC.	+16.72%	7.19B
AXONICS, INC.	+7.17%	3.4B
ENOVIS CORPORATION	-1.36%	3.03B
BEIJING BALANCE MEDICAL TECHNOLOGY CO.,LTD.	-8.73%	2.14B
SHANGHAI MICROPORT ENDOVASCULAR MEDTECH CO., LTD.	-10.15%	2B
DOUBLE MEDICAL TECHNOLOGY INC.	-22.81%	1.79B

Medical Devices & Implants